WOONSOCKET, R.I., Jan. 25, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced two agreements that total 264,000-megawatt hours with Constellation to purchase zero-emission, renewable energy equivalent to the annual electricity use of nearly 1,000 CVS Health locations in California, Washington, D.C., Delaware, Maryland and New Jersey.
"Investing in our planet and people's health are interconnected," said Sheryl Burke, chief sustainability officer and SVP of corporate social responsibility at CVS Health. "As our world continues to evolve, these sustainability investments we're making right now are increasingly important to create a healthier future for the communities we serve."
CVS Health will purchase energy and renewable energy certificates (RECs) through two separate long-term agreements with Constellation. These deals are made possible by Constellation's long-term agreements with solar projects located in California and Maryland. CVS Health will receive approximately 264,000 megawatt hours of energy per year through its retail agreement with Constellation, with that energy matched by Green-e® Energy Certified RECs sourced from other renewable facilities throughout the U.S.
"CVS Health continues to be a leader in supporting newly constructed renewable resources and steadfast in its journey towards embracing sustainable energy," said Jim McHugh, Chief Commercial Officer at Constellation. "We are thrilled to work with CVS Health once again and provide solutions towards a carbon-free future."
Supporting the development of renewable energy projects is an integral part of CVS Health's continued efforts to invest in initiatives and programs that focus on improving the world's health and addressing the environmental factors contributing to health inequities. To make a meaningful impact against climate change, the company is focused on reducing the carbon footprint of its direct operations and supply chain by increasing energy efficiency, implementing water-saving programs, eliminating waste, and reducing fuel usage.
CVS Health has now made five renewable energy investments since 2022. These two new investments with Constellation, the company's two agreements announced in 2023 and the first investment made in 2022 represent more than 500,000 MWh of clean, renewable energy. This is a significant share of the 2.2 million MWh of energy CVS Health used in 2022. They are important milestones as CVS Health continues to work toward sourcing 50% renewable energy by 2040.
CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health — whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system — and their personal health care — by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
Media Contact
Courtney Tavener
401-712-3698
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$57.76 |
Daily Change: | -0.31 -0.53 |
Daily Volume: | 4,777,417 |
Market Cap: | US$72.770B |
August 27, 2024 August 01, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB